文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

依维莫司洗脱生物可吸收支架与依维莫司洗脱金属支架治疗冠状动脉狭窄的比较(ABSORB II):一项为期3年的随机、对照、单盲、多中心临床试验

Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
PubMed 文献 · Lancet · 2016-10-30

ABSORB II试验将501例心肌缺血患者按2:1随机分为依维莫司洗脱生物可吸收支架组(335例,364处病变)与依维莫司洗脱金属支架组(166例,182处病变),随访3年。主要终点血管舒缩反应性两组无统计学差异(0.047 mm vs 0.056 mm,优效性p=0.49),晚期管腔丢失生物可吸收支架组大于金属支架组(0.37 mm vs 0.25 mm,非劣效性p=0.78),器械导向复合终点生物可吸收支架组更高(10% vs 5%,HR 2.17,95%CI 1.01-4.70)。

要点

  • 3年血管舒缩反应性两组无统计学差异:生物可吸收支架组0.047 mm vs 金属支架组0.056 mm,优效性p=0.49。
  • 晚期管腔丢失生物可吸收支架组0.37 mm大于金属支架组0.25 mm,非劣效性p=0.78,未达非劣效。
  • 器械导向复合终点生物可吸收支架组10% vs 金属支架组5%,HR 2.17(95%CI 1.01-4.70),主要由靶血管心肌梗死驱动。

核心结论

  • 试验未达到优效血管舒缩反应性和非劣效晚期管腔丢失的联合主要终点,金属支架晚期管腔丢失显著低于生物可吸收支架。
  • 生物可吸收支架组器械导向复合终点更高,主要由靶血管心肌梗死驱动,包括围手术期心肌梗死。
  • 3年时患者导向复合终点、心绞痛状态和运动试验在两器械间无统计学差异。

研究设计与样本

  • ABSORB II为前瞻性、随机、阳性对照、单盲、平行两组、多中心临床试验,纳入18-85岁有心肌缺血证据且不同心外膜血管存在一处或两处原发病变的患者。
  • 患者按2:1随机接受依维莫司洗脱生物可吸收支架(Absorb)或依维莫司洗脱金属支架(Xience)治疗,随机化按糖尿病状态和计划靶病变数量分层。
  • 2011年11月28日至2013年6月4日共纳入501例患者,随机分入生物可吸收支架组(335例,364处病变)或金属支架组(166例,182处病变)。
  • 3年随访主要终点为冠状动脉内硝酸酯给药后血管造影血管舒缩反应性优效性,联合主要终点为血管造影晚期管腔丢失非劣效性,非劣效界值0.14 mm。
  • 试验注册于ClinicalTrials.gov,编号NCT01425281。

主要发现

  • 3年血管舒缩反应性两组无统计学差异:生物可吸收支架组0.047 mm(SD 0.109)vs 金属支架组0.056 mm(0.117),优效性p=0.49。
  • 晚期管腔丢失生物可吸收支架组大于金属支架组:0.37 mm(0.45)vs 0.25 mm(0.25),非劣效性p=0.78。
  • 血管内超声测得最小管腔面积生物可吸收支架组4.32 mm²(SD 1.48)vs 金属支架组5.38 mm²(1.51),p<0.0001。
  • 器械导向复合终点生物可吸收支架组10% vs 金属支架组5%,风险比2.17(95%CI 1.01-4.70),log-rank检验p=0.0425,主要由靶血管心肌梗死驱动(6% vs 1%,p=0.0108),包括围手术期心肌梗死(4% vs 1%,p=0.16)。
  • 患者导向复合终点、西雅图心绞痛问卷评分和运动试验两组无统计学差异。

临床怎么用

  • 作者认为未来研究应探讨精确血管内影像在器械尺寸选择和优化生物可吸收支架植入中的临床影响。
  • 作者提出生物可吸收支架植入后延长双联抗血小板治疗的获益与必要性也可成为未来临床研究主题。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: No medium-term data are available on the random comparison between everolimus-eluting bioresorbable vascular scaffolds and everolimus-eluting metallic stents. The study aims to demonstrate two mechanistic properties of the bioresorbable scaffold: increase in luminal dimensions as a result of recovered vasomotion of the scaffolded vessel. METHODS: The ABSORB II trial is a prospective, randomised, active-controlled, single-blind, parallel two-group, multicentre clinical trial. We enrolled eligible patients aged 18-85 years with evidence of myocardial ischaemia and one or two de-novo native lesions in different epicardial vessels. We randomly assigned patients (2:1) to receive treatment with an everolimus-eluting bioresorbable scaffold (Absorb; Abbott Vascular, Santa Clara, CA, USA) or treatment with an everolimus-eluting metallic stent (Xience; Abbott Vascular, Santa Clara, CA, USA). Randomisation was stratified by diabetes status and number of planned target lesions. At 3 year follow-up, the primary endpoint was superiority of the Absorb bioresorbable scaffold versus the Xience metallic stent in angiographic vasomotor reactivity after administration of intracoronary nitrate. The co-primary endpoint is the non-inferiority of angiographic late luminal loss. For the endpoint of vasomotion, the comparison was tested using a two-sided t test. For the endpoint of late luminal loss, non-inferiority was tested using a one-sided asymptotic test, against a non-inferiority margin of 0·14 mm. The trial is registered at ClinicalTrials.gov, number NCT01425281. FINDINGS: Between Nov 28, 2011, and June 4, 2013, we enrolled 501 patients and randomly assigned them to the Absorb group (335 patients, 364 lesions) or the Xience group (166 patients, 182 lesions). The vasomotor reactivity at 3 years was not statistically different (Absorb group 0·047 mm [SD 0·109] vs Xience group 0·056 mm [0·117]; psuperiority=0·49), whereas the late luminal loss was larger in the Absorb group than in the Xience group (0·37 mm [0·45] vs 0·25 mm [0·25]; pnon-inferiority=0·78). This difference in luminal dimension was confirmed by intravascular ultrasound assessment of the minimum lumen area (4·32 mm2 [SD 1·48] vs 5·38 mm2 [1·51]; p<0·0001). The secondary endpoints of patient-oriented composite endpoint, Seattle Angina Questionnaire score, and exercise testing were not statistically different in both groups. However, a device-oriented composite endpoint was significantly different between the Absorb group and the Xience group (10% vs 5%, hazard ratio 2·17 [95% CI 1·01-4·70]; log-rank test p=0·0425), mainly driven by target vessel myocardial infarction (6% vs 1%; p=0·0108), including peri-procedural myocardial infarction (4% vs 1%; p=0·16). INTERPRETATION: The trial did not meet its co-primary endpoints of superior vasomotor reactivity and non-inferior late luminal loss for the Absorb bioresorbable scaffold with respect to the metallic stent, which was found to have significantly lower late luminal loss than the Absorb scaffold. A higher rate of device-oriented composite endpoint due to target vessel myocardial infarction, including peri-procedural myocardial infarction, was observed in the Absorb group. The patient-oriented composite endpoint, anginal status, and exercise testing, were not statistically different between both devices at 3 years. Future studies should investigate the clinical impact of accurate intravascular imaging in sizing the device and in optimising the scaffold implantation. The benefit and need for prolonged dual antiplatelet therapy after bioresorbable scaffold implantation could also become a topic for future clinical research. FUNDING: Abbott Vascular.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Serruys PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016. PMID: 27806897. doi:10.1016/S0140-6736(16)32050-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。